PAA 4.88% 21.5¢ pharmaust limited

Ann: Phase IIb Dog Trial Achieves Interim Clinical Endpoints, page-35

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 2,732 Posts.
    lightbulb Created with Sketch. 1497
    So help me decipher...

    Overall, including phase 2a and 2b :

    15 dogs enrolled.

    3 of the 15 were withdrawn as too far gone and MPL didn't help. (Good info to know, treat early.)

    1 of the remaining 12 had objective regression.
    6 of the remaining 12 has objective stable disease.

    12 of 12 completed the 28 day trial. So that leaves me with 5 unaccounted for. All I can assume is because they were not either objective regression or stable, they completed the course of treatment but it had little effect (and therefore may have had the same outcome if untreated).

    So is it fair to say 7 out of 15 had a successful outcome with MPL. If so that sounds ok but I am unsure what that is like in comparison to current standards of care. Any vets know?

    Also is it an assumption that this has somewhat disproven the biphasic hypothesis? Also good to know.
 
watchlist Created with Sketch. Add PAA (ASX) to my watchlist
(20min delay)
Last
21.5¢
Change
0.010(4.88%)
Mkt cap ! $104.6M
Open High Low Value Volume
20.5¢ 21.5¢ 20.5¢ $244.1K 1.163M

Buyers (Bids)

No. Vol. Price($)
3 71981 21.0¢
 

Sellers (Offers)

Price($) Vol. No.
21.5¢ 84173 3
View Market Depth
Last trade - 16.10pm 11/10/2024 (20 minute delay) ?
PAA (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.